Stockscreener 앱 받기
8.62%
전일 마감가:
$338.59
열려 있는:
$352.03
하루 거래량:
3.97M
Relative Volume:
1.39
시가총액:
$197.88B
수익:
$36.71B
순이익/손실:
$7.71B
주가수익비율:
25.82
EPS:
14.2284
순현금흐름:
$9.96B
1주 성능:
+7.47%
1개월 성능:
+12.25%
6개월 성능:
+21.81%
1년 성능:
+27.25%
1일 변동 폭
$342.38
$368.60
1주일 범위
$338.07
$368.60
52주 변동 폭
$261.43
$368.60
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
367.48 | 182.32B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,097.77 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
234.90 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
220.10 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
120.14 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
154.11 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Zacks Investment Research
BofA Securities reiterates Underperform rating on Amgen stock at $304 - Investing.com
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth - GlobeNewswire Inc.
Cantor Fitzgerald Raises Price Target for Amgen (AMGN) to $350 | - GuruFocus
Cantor Fitzgerald Increases Amgen (NASDAQ:AMGN) Price Target to $350.00 - MarketBeat
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act - TipRanks
Cantor Fitzgerald raises Amgen stock price target to $350 on strong earnings - Investing.com India
Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes
Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating - marketscreener.com
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus - TradingView
Amgen (NASDAQ:AMGN) Sets New 1-Year High Following Strong Earnings - MarketBeat
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Amgen's Diversified Portfolio and Growing Cardiovascular Focus Support a Wide Moat - Morningstar
Amgen stock reaches all-time high of $353.74 By Investing.com - Investing.com Canada
Amgen stock reaches all-time high of $353.74 - Investing.com
Morgan Stanley Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Leerink Partners Raises Amgen (AMGN) Price Target to $355 | AMGN Stock News - GuruFocus
Street View: Amgen banks on pipeline depth and long term weight-loss play - TradingView
Amgen (NASDAQ:AMGN) Price Target Raised to $355.00 - MarketBeat
Amgen Fell 4% Last Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge (AMGN) - Seeking Alpha
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Goldman Sachs Adjusts Price Target on Amgen to $415 From $403, Maintains Buy Rating - marketscreener.com
Amgen stock price target raised to $420 from $389 at TD Cowen - Investing.com
AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook - Finviz
Amgen posts double-digit revenue and EPS growth for 2025 - The Pharma Letter
Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation - simplywall.st
Amgen (NASDAQ:AMGN) Stock Unloaded Rep. David Taylor - MarketBeat
Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
A Decade of Rewards: $86 Bil From Amgen Stock - Trefis
Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products - Stocktwits
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges - GuruFocus
Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
Amgen (AMGN) Reports Strong 2025 Growth with Blockbuster Products - GuruFocus
Amgen (AMGN) Surpasses Q4 Expectations, Sets 2026 Guidance - GuruFocus
Amgen Q4 2025 slides: 10% revenue growth, robust pipeline advancement By Investing.com - Investing.com India
Amgen Beats Expectations as Top Drugs Boost Sales and Profit - Bloomberg.com
Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln - marketscreener.com
Amgen (AMGN) Q4 2025 Earnings Call Transcript - AOL.com
Amgen Q4 2025 slides: 10% revenue growth, robust pipeline advancement - Investing.com
Amgen Q4 Earnings Call Highlights - MarketBeat
Amgen Inc (NASDAQ:AMGN) Beats Q4 2025 Estimates and Provides Strong 2026 Revenue Guidance - Chartmill
Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings - Yahoo Finance
Amgen beats on both lines in Q4 and issues 2026 guidance (AMGN:NASDAQ) - Seeking Alpha
Amgen (AMGN) Surpasses Q4 Earnings Expectations with Strong Reve - GuruFocus
Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance Singapore
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
5.98%
2.09%
자본화:
|
볼륨(24시간):